Research programme: biodefence therapeutics - Morphotek/USAMRIID

Drug Profile

Research programme: biodefence therapeutics - Morphotek/USAMRIID

Alternative Names: Biodefense therapeutics - Morphotek/USAMRIID; MORAb-047; MORAb-048

Latest Information Update: 25 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Morphotek
  • Developer Morphotek; United States Army Medical Research Institute of Infectious Diseases
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Bacterial infections; Staphylococcal infections

Most Recent Events

  • 25 May 2010 Preclinical development is ongoing in the US
  • 26 Sep 2008 Morphotek Inc enter into an agreement to access Pivotal BioScience's LEC platform technology for the development of therapeutic monoclonal antibodies
  • 04 Oct 2007 Preclinical trials in Staphylococcal infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top